Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Progresses and Challenges

Hepatocellular carcinoma (HCC) is one of the most common malignant tumor in the world and its incidence is increasing in many countries. In recent years, with the deepening understanding of the immune and pathological mechanisms of HCC, immunotherapy based on the regulation of tumor immune microenvi...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Hao-Tian Liu, Meng-Jie Jiang, Zhu-Jian Deng, Le Li, Jian-Li Huang, Zhen-Xiu Liu, Le-Qun Li, Jian-Hong Zhong
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2021-10-01
Colecção:	Frontiers in Oncology
Assuntos:	immune checkpoint inhibitors (ICI) immune tolerance hepatocellular carcinoma (HCC) tyrosine kinase inhibitors (TKIs) overall survival (OS) progression-free survival (PFS)
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/fonc.2021.737497/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!